Xgene Pharmaceutical Reports Results from P-IIb Trial of XG005 for Post-Surgical Pain

Shots:

• The P-IIb trial is evaluating XG005 (1250mg or 750mg, BID, oral) vs PBO in patients (n=450) for managing acute pain after bunionectomy
• Results showed reduced pain intensity over 72hrs. post-surgery, with mild pain (<4 NRS) in high dose group vs severe pain (>7 NRS) in PBO; delayed rescue medication use of up to 8-fold in high dose group [medians: 31.47 (high dose) & 12.24 (low dose) vs 4.03hrs.)] & lower opioid use in both arms, with
• Morphine Equivalent Doses of 6.72mg (high dose) & 9.38mg (low dose) vs 23.86/24.68mg XG005 significantly reduced acetaminophen use [means: 1586.03mg (high dose) & 1975.89mg (low dose) vs 4812.7mg) over 72hrs. plus improved Patient Global Assessment (PGA) scores & sleep quality

Ref: Businesswire | Image: Xgene Pharmaceutical

Related News:- ADC Therapeutics Reports Enrollment Completion in P-III (LOTIS-5) Study of Zynlonta Plus Rituximab for 2L+ Diffuse Large B-Cell Lymphoma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com